Review of Disease Burden of Lung Cancer In China’s Beijing And Shanghai

Abstract

A199 for Chinese journals, were searched through to Dec. 31th, 2014. RESULTS: In 2010, incidence and mortality of lung cancer in China are 46.08/105 and 37.00/105. DALYs (disability adjusted life years) and economic burden of lung cancer are extremely high in both Beijing and Shanghai. DALYs of lung cancer are 42219.38 and 91962.18 in Beijing and Shanghai respectively. And average hospitalization expenditures per lung cancer inpatient are ¥38595.00 and ¥50026.65, among which average drug costs per inpatient are as high as ¥18139.65(46.97%) and ¥30356.00(60.68%). CONCLUSIONS: Lung cancer has made Chinese patients incur great loss in both DALYs and money, which is a conspicuous reminder to policy makers to pay more attention to management of the raging disease. And early prevention and screening of lung cancer should be priorities to slow increasing speed of disease burden.

Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey

“…Regarding medical expenditures of patients with lung cancer, drug expenditures accounted for the largest proportion and increased over time. This finding is consistent with other domestic research results regarding lung cancer costs [ 7 , 19 ]. Laboratory and inspection expenditures have continued to rise over the past decade.…”